Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2499${count})

  • Rapid Response Innovation Awards, 2014
    Role of Parkin and Its Opponent in Parkinson’s Disease Onset

    Study Rationale:       
    Parkin is an enzyme that adds molecules to proteins, including one called mitofusin, which bridges mitochondria (cell’s powerhouse) to the endoplasmic reticulum (structure...

  • Research Grant, 2014
    Validation of the Movement Disorders Society’s Clinical Criteria of Parkinson’s Disease

    Study Rationale:
    Diagnosis of Parkinson’s disease (PD) and other causes of parkinsonism is not always an easy task for physicians. An accurate diagnosis, however, is an essential aspect of care for...

  • Biomarker Development, 2015
    Comparison of Pre- and Post-mortem Cerebrospinal Fluid Levels of Proteins and Lipids

    Study Rationale:                   
    Alpha-synuclein aggregation in the brain is the main pathology of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) levels of alpha-synuclein are lower in PD. It...

  • Dyskinesia Challenge, 2015
    Biomarkers and Sensors for Levodopa-induced Dyskinesia

    Study Rationale:                   
    Levodopa is the gold-standard drug for treatment of Parkinson’s disease (PD), but chronic use is associated with serious motor complications called levodopa-induced...

  • Dyskinesia Challenge, 2015
    Targeting M4 Muscarinic Receptors for the Treatment of Levodopa-induced Dyskinesia

    Study Rationale:                   
    Levodopa-induced dyskinesia is thought to stem from sustained stimulation of D1 dopamine receptors (D1Rs). One potential strategy for diminishing excessive D1R...

  • Research Grant, 2015
    Neurorestorative Effects of a Sigma-1 Receptor Agonist in a Model of Parkinson’s Disease

    Study Rationale:                   
    In a previous MJFF-sponsored project, we evaluated PRE-084 (an experimental compound binding to the sigma-1 receptor) in pre-clinical models of Parkinson’s disease...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.